Emergent BioSolutions Inc. (EBS)

9.52 0.12 (1.32%)

As of 2025-10-16 18:18:23 EST

Emergent BioSolutions Inc. is an American multinational specialty biopharmaceutical company headquartered in Gaithersburg, Maryland. It develops vaccines and antibody therapeutics for infectious diseases and opioid overdoses, and it provides medical devices for biodefense purposes.

Traded asNYSE: EBS
ISINUS29089Q1058
CIK0001367644
LEI549300YW6TUOX8BE5103
EIN141902018
Sector—
IndustryPharmaceutical Preparations
CEOJoseph C. Papa
Employees1,600
Fiscal Year End1231
Address300 PROFESSIONAL DR, GAITHERSBURG, MD, 20879
Phone240-631-3200
Websitehttp://emergentbiosolutions.com
Stock Quotes
trading_symbolregistrant_nametimepricechangepercentage_change
EBSEmergent BioSolutions Inc.2025-10-16 18:18:239.520.121.32
This is a preview of the latest data. Subscribe to access the full data.
Company Information
trading_symbolcentral_index_keyregistrant_nameisin_numberlei_numberein_numberexchangesic_codesic_descriptionfiscal_year_endstate_of_incorporationaddress_streetaddress_cityaddress_stateaddress_zip_codeaddress_countryaddress_country_codephone_numbermailing_addressbusiness_addressformer_nameindustryfounding_datechief_executive_officernumber_of_employeeswebsitemarket_capshares_issuedshares_outstandingdescriptionupdate_time
EBS0001367644Emergent BioSolutions Inc.US29089Q1058549300YW6TUOX8BE5103141902018NYSE2834Pharmaceutical Preparations1231DE300 PROFESSIONAL DRGAITHERSBURGMD20879UNITED STATESUS240-631-3200300 PROFESSIONAL DR, GAITHERSBURG, MD, 20879300 PROFESSIONAL DR, GAITHERSBURG, MD, 20879——1998-09-05Joseph C. Papa1,600http://emergentbiosolutions.com360,700,00060,400,00053,351,099Emergent BioSolutions Inc. is an American multinational specialty biopharmaceutical company headquartered in Gaithersburg, Maryland. It develops vaccines and antibody therapeutics for infectious diseases and opioid overdoses, and it provides medical devices for biodefense purposes.2025-10-10 21:47:09
This is a preview of the latest data. Subscribe to access the full data.
EBS Stock Price (End-of-Day)
This is a preview of the latest data. Subscribe to access the full data.
EBS Stock Price (1-Minute)
This is a preview of the latest data. Subscribe to access the full data.
Market Cap
Fiscal YearMarket CapChange In Market CapPercentage Change In Market CapShares OutstandingChange In Shares OutstandingPercentage Change In Shares Outstanding
2024360,700,000-20,000,000-5.253554,337,0262,133,5934.0871
2023380,700,000-1,119,300,000-74.6252,203,4332,063,2754.115
20221,500,000,000-1,900,000,000-55.882450,140,158-361,263-0.7154
This is a preview of the latest data. Subscribe to access the full data.
Executive Compensation
Executive NameExecutive PositionFiscal YearSalaryBonusStock AwardsIncentive Plan CompensationOther CompensationTotal Compensation
Richard LindahlChief Financial Officer, Treasurer, Executive Vice President2024638,185799,506135,000541,10410,3502,311,320
Coleen GlessnerExecutive Vice President2024602,139747,5210507,1929,1862,053,213
Joseph PapaChief Executive Officer, President, Director2024800,0001,000,000516,0001,566,4747,0385,862,562
Haywood MillerChief Executive Officer2024218,7500000218,750
Paul WilliamsSenior Vice President2024469,560685,0010325,8828,0691,675,687
This is a preview of the latest data. Subscribe to access the full data.
Employee Count
Fiscal YearEmployee Count
2024900
20231,600
20222,500
This is a preview of the latest data. Subscribe to access the full data.
Income Statements
Fiscal Year202420232022
Revenue1,043,600,0001,049,300,0001,120,900,000
Cost Of Revenue185,900,000705,400,000693,700,000
Gross Profit213,000,000317,600,000385,800,000
Research And Development Expenses70,700,000111,400,000193,000,000
General And Administrative Expenses308,000,000368,400,000340,300,000
Operating Expenses———
Operating Income-108,700,000-726,400,000-172,700,000
Net Income-190,600,000-760,500,000-223,800,000
Earnings Per Share Basic-3.6-14.85-4.47
Earnings Per Share Diluted-3.6-14.85-4.47
Weighted Average Shares Outstanding Basic53,000,00051,200,00050,100,000
Weighted Average Shares Outstanding Diluted53,000,00051,200,00050,100,000
This is a preview of the latest data. Subscribe to access the full data.
Balance Sheet Statements
Fiscal Year202420232022
Cash And Cash Equivalents99,500,000111,700,000642,600,000
Marketable Securities Current———
Accounts Receivable154,500,000191,000,000158,400,000
Inventories311,700,000328,900,000351,800,000
Non Trade Receivables———
Other Assets Current———
Total Assets Current598,700,000679,500,0001,210,700,000
Marketable Securities Non Current———
Property Plant And Equipment270,600,000382,800,000817,600,000
Other Assets Non Current18,900,000194,300,000191,300,000
Total Assets Non Current275,200,000392,400,000826,700,000
Total Assets1,389,700,0001,823,200,0003,166,600,000
Accounts Payable60,900,000112,200,000103,500,000
Deferred Revenue4,800,00027,200,00026,400,000
Short Term Debt0413,700,000957,300,000
Other Liabilities Current27,700,00032,700,00045,900,000
Total Liabilities Current162,400,000651,300,0001,229,900,000
Long Term Debt700,000,000868,400,0001,413,800,000
Other Liabilities Non Current39,100,00028,900,00033,400,000
Total Liabilities Non Current744,500,000522,600,000553,700,000
Total Liabilities906,900,0001,173,900,0001,783,600,000
Common Stock100,000100,000100,000
Retained Earnings-212,400,000-21,800,000734,000,000
Accumulated Other Comprehensive Income-5,200,000-5,700,0003,100,000
Total Shareholders Equity482,800,000649,300,0001,383,000,000
This is a preview of the latest data. Subscribe to access the full data.
Cash Flow Statements
Fiscal Year202420232022
Depreciation And Amortization108,800,000125,100,00083,400,000
Share Based Compensation Expense18,000,00023,100,00045,100,000
Other Non Cash Income Expense-6,500,000-13,000,000-6,400,000
Change In Accounts Receivable24,400,00021,600,000-114,700,000
Change In Inventories24,500,000-600,00051,900,000
Change In Non Trade Receivables———
Change In Other Assets———
Change In Accounts Payable-33,000,00010,600,000-14,000,000
Change In Other Liabilities12,300,000-55,700,000-66,700,000
Cash From Operating Activities58,700,000-206,300,000-34,100,000
Purchases Of Marketable Securities———
Sales Of Marketable Securities———
Acquisition Of Property Plant And Equipment22,900,00051,600,000115,800,000
Acquisition Of Business———
Other Investing Activities———
Cash From Investing Activities125,200,000212,300,000-381,300,000
Tax Withholding For Share Based Compensation1,200,0002,500,0005,900,000
Payments Of Dividends———
Issuance Of Common Stock08,400,000—
Repurchase Of Common Stock0075,500,000
Issuance Of Long Term Debt65,000,00020,000,000598,000,000
Repayment Of Long Term Debt284,200,000398,800,0000
Other Financing Activities1,500,0001,800,0005,000,000
Cash From Financing Activities-190,000,000-535,700,000481,200,000
Change In Cash-6,100,000-530,900,00066,300,000
Cash At End Of Period99,500,000111,700,000642,600,000
Income Taxes Paid26,500,00052,800,0006,200,000
Interest Paid64,000,00068,300,00033,000,000
This is a preview of the latest data. Subscribe to access the full data.
Key Metrics
Fiscal Year202420232022
Earnings Per Share-3.6-14.85-4.47
Price To Earnings Ratio-2.6556-0.1616-2.6421
Earnings Growth Rate-75.7576232.2148-203.4722
Price Earnings To Growth Ratio0.0351-0.00070.013
Book Value Per Share9.109412.681627.6048
Price To Book Ratio1.04950.18920.4278
Ebitda15,700,000-494,700,000-96,900,000
Enterprise Value1,107,180,0001,293,280,0002,320,181,000
Dividend Yield———
Dividend Payout Ratio———
Debt To Equity Ratio1.44991.97461.7145
Capital Expenditures-3,400,000-309,700,000100,900,000
Free Cash Flow62,100,000103,400,000-135,000,000
Return On Equity-0.3948-1.1713-0.1618
One Year Beta3.57732.16731.4512
Three Year Beta1.95041.50011.1999
Five Year Beta1.44161.24981.1688
This is a preview of the latest data. Subscribe to access the full data.
Insider Transactions
Insider NameRelationship To IssuerTransaction DateAmount Of SecuritiesAcquired Or DisposedSecurities Owned Following Transaction
Glessner ColeenEVP, Quality & Ethics, and CPL2025-10-0730,608D144,319
Zoon Kathryn CDirector2025-08-157,086D71,799
DeGolyer Donald WDirector2025-08-127,844D137,659
Hartzel WilliamSVP, Bioservices2025-07-114,263D103,692
LINDAHL RICHARD SEVP, Chief Financial Officer2025-06-082,733D296,492
This is a preview of the latest data. Subscribe to access the full data.
House Trading
Name Of Reporting PersonReport DateStateTransaction TypeTransaction DateOwner TypeAmount
Steve Cohen2025-01-10TN09Sale2024-12-11—$1,001 - $15,000
Josh Gottheimer2021-12-13NJ05Sale2021-11-05Joint$1,001 - $15,000
Steve Cohen2019-09-12TN09Sale2019-08-29—$15,001 - $50,000
This is a preview of the latest data. Subscribe to access the full data.
Institutional Holdings
Investor NamePeriod Of ReportMarket ValueAmount Of SecuritiesPrice Per Security
Lowe Wealth Advisors, LLC2025-09-30353408.825
CWM, LLC2025-09-30151,00017,0678.8475
Pacer Advisors, Inc.2025-09-304,733,297536,6558.82
HARBOR CAPITAL ADVISORS, INC.2025-09-30187,00021,1758.8312
Farther Finance Advisors, LLC2025-09-3011,7841,3368.8204
This is a preview of the latest data. Subscribe to access the full data.
Mutual Fund Holdings
Registrant NamePeriod Of ReportFund NameFund SymbolAmount Of UnitsValue In UsdPercentage Value Compared To Assets
TRUST FOR PROFESSIONAL MANAGERS2025-08-31Column Small Cap FundCFSLX8,94474,235.20.0155
Pacer Funds Trust2025-07-31Pacer US Small Cap Cash Cows ETFCALF529,1703,111,519.60.0777
Pacer Funds Trust2025-07-31Pacer Trendpilot International ETFPTIN2,775255,088.330.1638
Pacer Funds Trust2025-07-31Pacer Trendpilot European Index ETFPTEU1,489136,874.420.3877
INCOME FUND OF AMERICA2025-07-31Class CIFACX211,45119,334,506.870.0144
This is a preview of the latest data. Subscribe to access the full data.